Impact of lipoprotein(a) levels on recurrent cardiovascular events in patients with premature coronary artery disease
- 47 Downloads
Lipoprotein(a) [Lp(a)] is an independent risk factor for atherosclerotic cardiovascular disease, acting by either accelerating atherosclerosis progression or inducing a prothrombotic/antifibrinolytic systemic milieu [1, 2, 3]. Several studies support the relevant role of Lp(a) in the occurrence of coronary events, especially in patients with premature coronary artery disease (CAD) [4, 5, 6]. However, the association of elevated Lp(a) levels with the risk of recurrent cardiovascular events in patients with a prior coronary event optimally treated with statins remains controversial . We sought to assess the impact of Lp(a) levels on the recurrence of cardiovascular events in patients with premature CAD treated with percutaneous coronary intervention (PCI).
This prospective single-center study enrolled consecutive young patients (aged less than 50 years) undergoing first-ever PCI for stable CAD (SCAD) or acute coronary syndrome (ACS) (both ST-segment elevation...
KeywordsLipoprotein(a) Dyslipidemia Acute coronary syndrome Coronary artery disease Percutaneous coronary intervention
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
Statement of human and animal rights
The study was carried out according to Declaration of Helsinki.
Patients gave their informed consent to participate to the study.
- 2.Gragnano F, Calabrò P (2018) Role of dual lipid-lowering therapy in coronary atherosclerosis regression: evidence from recent studies. Atherosclerosis 269:219–228. https://doi.org/10.1016/j.atherosclerosis.2018.01.012 CrossRefGoogle Scholar
- 3.Fogacci F, Cicero AF, D’Addato S, D’Agostini L, Rosticci M, Giovannini M, Bertagnin E, Borghi C, Brisighella Heart Study Group (2017) Serum lipoprotein(a) level as long-term predictor of cardiovascular mortality in a large sample of subjects in primary cardiovascular prevention: data from the Brisighella Heart Study. Eur J Intern Med 37:49–55. https://doi.org/10.1016/j.ejim.2016.08.018 CrossRefGoogle Scholar
- 5.Rallidis LS, Pavlakis G, Foscolou A et al (2018) High levels of lipoprotein (a) and premature acute coronary syndrome. Atherosclerosis 269:29–34. https://doi.org/10.1016/j.atherosclerosis.2017.12.011 CrossRefGoogle Scholar
- 7.Schwartz GG, Ballantyne CM, Barter PJ et al (2018) Association of lipoprotein(a) with risk of recurrent ischemic events following acute coronary syndrome: analysis of the dal-outcomes randomized clinical trial. JAMA Cardiol 3:164–168. https://doi.org/10.1001/jamacardio.2017.3833 CrossRefGoogle Scholar
- 8.Milionis HJ, Filippatos TD, Loukas T et al (2006) Serum lipoprotein(a) levels and apolipoprotein(a) isoform size and risk for first-ever acute ischaemic nonembolic stroke in elderly individuals. Atherosclerosis 187:170–176. https://doi.org/10.1016/j.atherosclerosis.2005.08.036 CrossRefGoogle Scholar
- 12.Shapiro MD, Minnier J, Tavori H, Kassahun H, Flower A, Somaratne R, Fazio S (2019) Relationship between low-density lipoprotein cholesterol and lipoprotein(a) lowering in response to PCSK9 inhibition with evolocumab. J Am Heart Assoc 8:e010932. https://doi.org/10.1161/JAHA.118.010932 CrossRefGoogle Scholar
- 14.Schettler VJJ, Neumann CL, Peter C et al (2017) Current insights into the German lipoprotein apheresis registry (GLAR)—almost 5 years on. Atheroscler Suppl 30:50–55. https://doi.org/10.1016/j.atherosclerosissup.2017.05.006 CrossRefGoogle Scholar
- 15.Viney NJ, van Capelleveen JC, Geary RS et al (2016) Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials. Lancet 388:2239–2253. https://doi.org/10.1016/S0140-6736(16)31009-1 CrossRefGoogle Scholar